1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH PA-06-392 is a 2006 program announcement (PA prefix, year 06). These announcements typically have 3-year lifespans and this one would have expired by 2009. The URL returns HTTP 403.
Research on Autism and Autism Spectrum Disorders (R21) is sponsored by National Institutes of Health (NIH). This Funding Opportunity Announcement (FOA) solicits NIH Exploratory/Developmental Research Grant (R21) applications for research aimed at characterizing, understanding, and treating etiological and pathophysiological mechanisms common to both Fragile X syndrome (FXS) and autism…
Get alerted about grants like this
Save a search for “National Institutes of Health (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Expired PA-06-392: Research on Autism and Autism Spectrum Disorders (R21) This notice has expired. Check the NIH Guide for active opportunities and notices. Part I Overview Information Department of Health and Human Services Participating Organizations of Health (NIH), ( http://www.
nih. gov ) Components of Participating Organizations National Institute of Mental Health (NIMH), ( http://www. nimh.
nih. gov ) National Institute on Deaf ness and Other Communication Disorders (NIDCD), ( http://www. nidcd.
nih. gov ) National Institute of Child Health and Human Development (NICHD), ( http://www. nichd.
nih. gov ) Nati onal Institute of Neurological Disorders and Stroke (NINDS), ( http://www. ninds.
nih. gov ) National Institute of Environmental Health Sciences (NIEHS), ( http://www. niehs.
nih. gov ) National Institute of Nursing Research (NINR), ( http://www. ninr.
nih. gov ) Office of Dietary Supplements (ODS), ( http: / /ods . od.
nih. gov ) Title: Research on Autism and Autism Spectrum Disorders (R21) This is a reissue of PA-04-085 , which was previously released April 2, 2004, and is now divided into separate FOAs for R01, R21, and R03 funding mechanisms. Update: The following update relating to this announcement has been issued: March 30, 2010 - This PA has been reissued as (PA-10-160).
January 16, 2009 - See Notice (NOT-MH-09-003) The purpose of this notice is to extend the expiration dates until September 8, 2009. September 17, 2007 - Expiration Date adjusted to accommodate recent changes to standing submission deadlines, per NOT-OD-07-093. NOTICE: Applications submitted in response to this FOA for Federal assistance must be submitted electronically through Grants.
gov ( http://www. grants. gov ) using the SF424 Research and Related (R&R) forms and SF424 (R&R) Application Guide.
APPLICATIONS MAY NOT BE SUBMITTED IN PAPER FORMAT. This FOA must be read in conjunction with the application guidelines provided with this announcement in Grants. gov/Apply for Grants (hereafter called Grants.
gov/Apply). A registration process is necessary before submission and applicants are highly encouraged to start the process at least 4 weeks prior to the grant submission date. See Section IV .
Announcement (PA) Number: PA-06-392 Domestic Assistance Number(s) 93. 242, 93. 113, 93.
115, 93. 173, 93. 361, 93.
865, Release/Posted Date: May 4, 2006 Opening Date: May 4 , 2006 (earliest date an application may be submitted to Grants. gov). On time submission requires that applications be successfully submitted to Grants.
gov no later than 5:00 p. m. local time (of applicant institution/organization).
Intent Receipt Date(s): Not Applicable Application Submission Date(s): dates apply, please see http://grants1. nih. gov/grants/funding/submissionschedule.
htm for AIDS Application Submission Date(s): Not Peer Review Date(s): Standard dates apply, please see http://grants1. nih. gov/grants/funding/submissionschedule.
htm#reviewandaward. Council Review Date(s): Standard dates apply, please see http://grants1. nih.
gov/grants/funding/submissionschedule. htm#reviewandaward . Earliest Anticipated Start Date(s): St andard dates apply, please see http://grants1.
nih. gov/grants/funding/submissionschedule. htm#reviewandaward .
Additional Information To Be Available Date (Activation Expiration Date: New Date September 8, 2009 (per NOT-MH-09-003 ), Original Expiration Date: March 2, 2009 (Changed to May 8, 2009 per NOT-OD-07-093 ) Additional Overview Content This funding opportunity announcement (FOA) solicits Exploratory/Developmental (R21) grant applications for the support of research designed to elucidate the diagnosis, epidemiology, etiology, genetics, treatment, and optimal means of service delivery in relation to Autistic Disorder ("autism") and autism spectrum disorders (Rett's Disorder, Childhood Disintegrative Disorder, Asperger's Disorder, Pervasive Developmental Disorder-Not Otherwise Specified, or "Atypical Autism").
Basic, clinical, and applied studies are This FOA is meant to support the broad research goals of the Autism Research Matrix ( http://iacc. hhs. gov/reports/2006/evaluating-progress-autism-matrix-nov17.
shtml ) This FOA will utilize the Exploratory/Developmental (R21) grant mechanism and runs in parallel with FOAs of identical s cientific scope that solicit applications under the small research grant (R03) mechanism as stated in PA-06-391 and the NIH Research Project Grant (R01) as stated in PA-06-390 . Applicants for the R03 and R01 awards must follow the guidelines for submission in their respective announcements.
Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.
The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.
Eligible organizations: For profit organizations; Non-profit organizations; Public or private institutions, such as universities, colleges, hospitals and laboratories; Units of State government; Units of local government; Eligible institutions of the Federal government; Domestic institutions; Foreign institutions; Faith-based or community-based organizations; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); and Indian/Native American Tribally Designated Organization.
Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
Applicants may submit more than one application, provided each application is scientifically distinct. application materials. The SF424 (R&R) Application Guide for this FOA is located at these Web sites: http://grants1.
nih. gov/grants/funding/424/SF424_RR_Guide_General_Ver2. doc http://grants1.
nih. gov/grants/funding/424/SF424_RR_Guide_General_Ver2. pdf For general information on SF424 (R&R) Application and Electronic Submission, see these the following Web sites: SF424 (R&R) Application and Electronic Submission Information: http://grants.
nih. gov/grants/funding/424/index. htm General information on Electronic Submission of Grant Applications: http://era.
nih. gov/ElectronicReceipt/ Telecommunications for the hearing impaired is available at: TTY 301-451-5936. Part I Overview Information Part II Full Text of Announcement Section I.
Funding Opportunity Section II. Award Information 2. Cost Sharing or Matching 3.
Other - Special Eligibility Criteria Section IV. Application and 1. Request Application Information 2.
Content and Form of Application Submission 3. Submission Dates and Times A. Submission, Review, and 4.
Intergovernmental Review 6. Other Submission Requirements Section V. Application Review 2.
Review and Selection Process A. Additional Review Criteria B. Additional Review Considerations D.
Sharing Research Resources 3. Anticipated Announcement and Award Dates Section VI. Award Administration 2.
Administrative and National Policy Requirements Section VII. Agency Contact(s) 1. Scientific/Research Contact(s) 2.
Peer Review Contact(s) 3. Financial/Grants Management Contact(s) Section VIII. Other Information - Required Federal Citations - Full Text of Announcement Section I.
Funding Opportunity Current classification systems (e.g., DSM-IV) include five separate diagnoses under the Pervasive Developmental Disorders: Autistic Disorder, Rett's Disorder, Childhood Disintegrative Disorder, Asperger's Disorder, and Pervasive Developmental Disorder Not Otherwise Specified. Collectively, these Pervasive Developmental Disorders are often referred to as Autism Spectrum Disorders.
These disorders share a cluster of impairments in reciprocal social interaction and communication and/or the presence of stereotyped behavior, interests, and activities. These complex disorders are usually of lifelong duration and affect multiple aspects of development, learning, and adaptation in the community, and thus represent a pressing public health need.
The etiologies of these disorders are poorly understood, but are thought to include genetic, metabolic, immunologic, or infectious or other environmental influences. Clinical research involving these disorders requires well-integrated, multi-disciplinary, methodologically-rigorous scientific approaches and access to a sufficient number of well-characterized patients with these disorders.
Basic research into the pathophysiology of autism and autism spectrum disorders, including research on brain mechanisms and genetics, is of special interest. Also of high priority are clinical and applied investigations that may lead to the development of diagnostic research instruments, treatments, and intervention strategies.
Specific areas of interest thus include epidemiology, early identification and diagnosis, genetic studies, brain mechanisms, communication skills, cognitive neuroscience, psychosocial (behavioral) interventions, pharmacological and other biological interventions, and support and rehabilitative services across the life-span, including adulthood and the transition to adulthood.
Areas of interest include, but need not be limited to, the following: Epidemiology: Studies of the genetic and environmental epidemiology of autism to determine risk and protective processes in the etiology of autism, including environmental exposures during pregnancy and early childhood; longitudinal studies of high-risk populations; epidemiologic research on interactive genetic and environmental processes that increase or decrease risk for autism; research on the expression of the full range of autism spectrum disorders; studies of their developmental course across the life-span; studies that characterize the range of expression within families; and research on co-occurring features, especially research that characterizes and quantifies risk and protective processes associated with co-occurrence.
Also of interest are clinical epidemiologic studies of autism spectrum disorders in clinical settings, including studies of clinical decision-making in personal-encounter care for individuals and families.
Identification, and Diagnosis: Key diagnostic and phenotypic features associated with various stages of development; development of new screening tools for use in a variety of settings; assessment of comorbid features including hyperactivity, attentional dysfunctions, epilepsy, and obsessive and compulsive symptoms; the creation of new measures to be used in longitudinal studies and measures that further differentiate the subtypes of autism spectrum disorders; and, developmental factors relevant to reliable and valid diagnosis.
Genetic Studies: Family-based association analysis and other linkage disequilibrium approaches that aim to identify specific susceptibility genes; studies of epigenetic mechanisms and long range control of gene expression; high-resolution mapping and positional cloning studies; resolution of locus heterogeneity; analysis of the interaction of autism susceptibility genes with environmental exposures and/or genes responsive to environmental insult; testing for potential candidate genes.
An area of particular interest is the effect of genetic factors on therapeutic drug response in autistic individuals (see Pharmacogenomics, below).
Brain Mechanisms: Studies of brain mechanisms underlying the development, regulation, and modulation of behaviors characterizing autism and autism spectrum disorders, particularly those mechanisms involving communication and social interaction; studies of brain mechanisms and biological factors underlying autistic regression, or the loss of previously acquired skills; studies of brain mechanisms involved in the development of abnormal electroencephalograms and epilepsy and studies to clarify the subtypes of seizures and seizure disorders in autism; studies to define the neurobiological basis of neurological abnormalities and neuropsychiatric symptoms, including motor stereotypies, gait abnormalities, akinesias, dyskinesias, obsessive/compulsive traits, and the exacerbation of these symptoms, including the role of neuroimmune/autoimmune factors; studies that seek to define basic processing deficits using neuropsychological and cognitive neuroscience techniques; studies to develop animal models of brain dysfunction in autism and autism spectrum disorders, based on either genetic or environmental factors or their interaction.
Developmental studies of relevant behaviors during infancy including attention to social and nonsocial stimuli, affective behavior, gaze, vocalization, imitation, initiative, reciprocity, attachment, play, compliance, and self-recognition and their emergence in children with autism and autistic spectrum disorders; research on the delays and deviations in social behavior and cognition during preschool and middle school, including empathy, receptive social cognitive deficits (i.e., difficulties understanding others), and expressive difficulties; studies leading to more sophisticated tests of higher cognitive functioning, especially in social, communicative, reasoning, and problem-solving areas, as well as tests of basic attentional, emotional and cognitive deficits that may underlie these deficits or be precursors to them; studies of theory of mind, of unconventional verbal behaviors, and of the sensory-motor factors involved in relevant social cognition; and the development, validation, and refinement of interventions designed to address deficits in complex social and cognitive abilities or their developmental precursors; interventions designed to lessen or remediate cognitive deficits.
Longitudinal, developmental studies of behaviors that are precursors to later communication and their emergence in children with autism and autistic spectrum disorders; sensory, motor, and social-cognitive impairments that impact upon interaction and communication; predictors of loss of or regression in expressive language abilities; interventions designed to remediate communication and related deficits across the life-span.
Pharmacological/Biological Interventions: Studies aimed at developing and testing the efficacy and safety of pharmacological agents that specifically target the core features of autism and autistic spectrum disorders; studies of the efficacy and safety of pharmacological and combined treatments for the most common and impairing psychopathology associated with autism (e.g., hyperactivity, impulsivity, aggression, self-injury, and obsessive-compulsive symptoms); studies that relate characteristics of individuals (or diagnostic subtypes) to therapeutic response and treatment outcomes (also see Pharmacogenomics , below); new approaches to treatment that build on advances in neuroscience, genetics, immunology, and other neurobiologic fields; focused interventions that test specific theories or hypotheses regarding possible neuropathogenesis; studies that address the benefits of combined drug and cognitive, behavioral, or psychosocial interventions; development of innovative methodologies and outcome Construction and analysis of SNP haplotypes that predict therapeutic response or adverse reactions to drugs; correlation of drug response profiles with intermediate phenotypes (e.g., brain imaging, neurophysiology, learning and memory, sustained attention); identification of biomarkers to resolve clinical heterogeneity and heterogeneity of therapeutic drug response; application of high-throughput approaches to screen for drug candidates metabolized by or inhibitors of polymorphic drug-metabolizing enzymes, e.g., CYP2D6; studies of genetically determined functional changes in nuclear and cell surface receptors to explain the ineffectiveness of therapeutic agents and adverse or paradoxical drug responses; studies of allelic variation occurring in individual transporter genes that are associated with a functional consequence.
Psychosocial Interventions: Studies developing new treatments (e.g., behavioral, cognitive-behavioral) and studies validating, refining, and comparing approaches to the treatment of persons with autism and autism spectrum disorders and their families, as well as studies that analyze and define the critical features of effective intervention; studies that relate characteristics of individuals (or diagnostic subtypes) to treatment outcomes; research on relevant contextual factors including physical and community environments, parent-child and sibling-child relationship factors, and peer-child interactions; studies addressing generalization or the transfer of learning from one setting to another; studies that develop and test interventions for infants and toddlers with confirmed or suspected autism spectrum disorders; studies that develop and test interventions to outcome in school and community settings throughout the lifespan; development of innovative methodologies and outcome measures.
Services Research: Research on the organization, delivery, coordination, and financing of services for persons with autism spectrum disorders, and their families, within or across service settings; studies aimed at better identifying and addressing changes in service and rehabilitative needs across the life-span, including during transitions from childhood to adolescence, and adolescence to adulthood; interventions to improve the quality and outcomes of treatment and rehabilitation services; studies to develop improved measures of adaptive capabilities for children, adolescents, and adults with autism spectrum disorders; studies of ways to coordinate or integrate services across settings including specialty mental health, general health, and other settings such as educational, vocational, and housing services, in order to maximize receipt of appropriate services; and research on the economic factors effecting the delivery of needed services and treatments including cost-benefit, cost-effectiveness, and cost utility analyses of service interventions.
The evolution and vitality of the biomedical sciences require a constant infusion of new ideas, techniques, and points of view. These may differ substanti ally from current thinking or practice and may not yet be supported by substantial preliminary data.
By using the R21 mechanism, the NIH seeks to foster the introduction of novel scientific ideas, model systems, tools, agents, targets, and technologies th at have the potential to substantially advance biomedical research. The R21 mechanism is intended to encourage new exploratory and developmental research projects.
For example, such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Another example could include the unique and innovative use of an existing methodology to explore a new scientific area.
These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Applications for R21 a wards should describe projects distinct from those supported through the traditional R01 mechanism.
For example, long-term projects, or projects designed to increase knowledge in a well-established area, will not be considered for R21 awards. Application s submitted under this mechanism should be exploratory and novel.
These studies should break new ground or extend previous discoveries toward new directions or See Section VIII, Other Information - Required Federal Citations , for policies related to this This FOA will use the NIH Exploratory/Developmental Research Grant (R21) award mechanism . As an applicant, you will be solely responsible for planning, directing, and executing the proposed project. This FOA uses just-in-time concepts.
It also uses the modular budget formats (see the Modular Applications and Awards section Grants Policy Statement . Specifically, since you are submitting an application with direct costs in each year of $250,000 or less (excluding consortium Facilities and Administrative [F&A] costs), use the PHS398 Modular Budget component provided in the SF424 (R&R) Application Package and SF424 (R&R) Application Guide (see specifically Section 5.
4, Modular Budget Component, of the Application Guide). Exploratory/developmental grant support is for new projects only; competing renewal (formerly competing continuation ) applications will not be accepted. Up to two resubmissions (formerly revisions/amendments") of a previously reviewed exploratory/developmental grant application may be submitted.
See NOT-OD-03-041 , Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.
Although the financial plans of the Institutes and Centers (ICs) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total project period for an application submitted in response to this funding opportunity may not exceed 2 years.
Although the size of award may vary with the scope of research proposed, it is expected that applications wi ll stay within the budgetary guidelines for an exploratory/developmental project; direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.
Applicants may request direct costs i n $25,000 modules, up to the total direct costs limitation of $275,000 for the combined two-year award period. NIH grants policies as described in the NIH Grants Policy Statement will apply t o the applications submitted and awards made in response to this Program Announcement funding opportunity.
Facilities and Administrative (F&A) costs requested by consortium participants are not included in the direct cost limitation. See NOT-OD-05-004 . III.
Eligibility Information 1. A.
Eligible Institutions You may submit an application(s) if your organization has any of the following characteristics: Public or private institutions, such as universities, colleges, hospitals, and laboratories Units of State government Units of Local government Eligible agencies of the Federal government Faith-based or community-based organizations Tribal Government (Federally Recognized) Tribal Government (Other than Federally Recognized) Indian/Native American Tribally 1.
B. Eligible Individuals individual with the skills, knowledge, and resources necessary to carry out the proposed research as the Project Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
This program does not require cost sharing as defined in the current NIH Grants Policy Statement . Applicants may submit more than one application, provided each application is scientifically distinct. IV.
Application and Submission Information To download a SF424 (R&R) Application Package and SF424 (R&R) Application Guide for completing the SF424 (R&R) forms for this FOA, link to http://www. grants. gov/Apply/ and follow the directions provided on that Web site.
A one-time registration is required for institutions/organizations at both: Grants. gov ( http://www. grants.
gov/GetStarted ) eRA Commons ( http://era. nih. gov/ElectronicReceipt/preparing.
htm ) PD/PIs should work with their institutions/organizations to make sure they are registered in the eRA Commons. Several additional separate actions are required before an applicant institution/organization can submit an electronic application, as follows: 1) Organizational/Institutional Registration in Grants.
gov/Get Started Your organization will need to obtain a Data Universal Number System (DUNS) number and register with the Central Contractor Registration (CCR) as part of the Grants. gov registration process. If your organization does not have a Taxpayer Identification Number (TIN) or Employer Identification Number (EIN), allow for extra time.
A valid TIN or EIN is necessary for CCR registration. The CCR also validates the EIN against Internal Revenue Service records, a step that will take an additional one to two Direct questions regarding Grants. gov Grants.
gov Customer Support Business Hours: M-F 7:00 a. m. - 9:00 p.
m. Eastern Time 2) Organizational/Institutional Registration in the eRA Commons To find out if an organization is already Commons-registered, see the " List of Grantee Organizations Registered in NIH eRA Commons. Direct questions regarding the Commons Phone: 301-402-7469 or 866-504-9552 (Toll Free) Business hours M-F 7:00 a.
m. 8:00 p. m.
Eastern Time 3) Project Director/Principal Investigator (PD/PI) Registration in the NIH eRA Commons: Refer to the NIH eRA Commons System (COM) The individual designated as the PD/PI on the application must also be registered in the NIH eRA Commons. It is not necessary for PDs/PIs to register with Grants. gov. The PD/PI must hold a PD/PI account in the Commons and must be affiliated with the applicant organization.
This account cannot have any other role attached to it other than the PD/PI. This registration/affiliation must be done by the Authorized Organization Representative/Signing Official (AOR/SO) or their designee who is already registered in the Commons. Both the PD/PI and AOR/SO need separate accounts in the NIH eRA Commons since both are authorized to view the application image.
that if a PD/PI is also an NIH peer-reviewer with an Individual DUNS and CCR registration, that particular DUNS number and CCR registration are for the individual reviewer only. These are different than any DUNS number and CCR registration used by an applicant organization.
Individual DUNS and CCR registration should be used only for the purposes of personal reimbursement and should not be used on any grant applications submitted to the Federal Several of the steps of the registration process could take four weeks or more. Therefore, applicants should immediately check with their business official to determine whether their organization/institution is already registered in both Grants.
gov and the Commons . The NIH will accept electronic applications only from organizations that have completed all Applicants must download the SF424 (R&R) application forms and SF424 (R&R) Application Guide for this FOA through Grants. gov/Apply .
Only the forms package directly attached to a specific FOA can be used. You will not be able to use any other SF424 (R&R) forms (e.g., sample forms, forms from another FOA), although some of the "Attachment" files may be useable for more than one FOA. For further assistance, contact GrantsInfo: Telephone 301-710-0267, Email: [email protected] .
Telecommunications for the hearing impaired: TTY 2. Content and Form of Application Submission Prepare all applications using the SF424 (R&R) application forms and in accordance with the SF424 (R&R) Application Guide ( MS The SF424 (R&R) Application Guide is critical to submitting a complete and accurate application to NIH.
There are fields within the SF424 (R&R) application components that, although not marked as mandatory, are required by NIH ( e.g., the Credential log-in field of the Research & Related Senior/Key Person Profile component must contain the PD/PI’s assigned eRA Commons User ID ). Agency-specific instructions for such fields are clearly identified in the Application Guide.
For additional information, see Tips and Tools for Navigating Electronic Submission on the front page of Electronic Submission of Grant The SF424 (R&R) application is comprised of data arranged in separate components. Some components are required, others are optional. The forms package associated with this FOA in Grants.
gov/APPLY will include all applicable components, required and optional.
A completed application in response to this FOA will include the following components: Research & Related Project/Performance Site Research & Related Other Project Information Research & Related Senior/Key Person PHS398 Cover Page Supplement Research & Related Subaward Budget Attachment(s) Note: While both budget components are included in the SF424 (R&R) forms package, the NIH R21 uses ONLY the PHS398 Modular Budget.
(Do not use the detailed Research & Related Several special provisions apply to applications submitted by foreign organizations: back of customs and import fees is not allowed. Every effort should be made to comply with the format specifications, which are based upon a standard U.S. paper size of 8. 5" x 11" for up to 8% administrative costs (excluding equipment) may be requested ( http://grants.
nih. gov/grants/guide/notice-files/NOT-OD-01-028. html ).
must comply with Federal/NIH policies on human subjects, animals, and Organizations must comply with Federal/NIH biosafety and biosecurity regulations. See Section VI. 2 .
, Administrative and National Policy Requirements. For additional information, see the NIH Grants Policy Statement regarding foreign grants: http://grants. nih.
gov/grants/policy/nihgps_2003/NIHGPS_Part12. htm#_Toc54600260 . research should provide special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions in other countries that are not readily available in the United States or that augment existing U.S. resources.
3. Submission Dates and Times 3. A.
Submission, Review, and Opening Date: May 4 , 2006 (earliest date an application may be submitted Intent Receipt Date(s): Not applicable Application Submission Date(s): http://grants. nih. gov/grants/funding/submissionschedule.
htm AIDS Application Submission Date(s): http://grants1. nih. gov/grants/funding/submissionschedule.
htm#AIDS Peer Review Date(s): http://grants1. nih. gov/grants/funding/submissionschedule.
htm#reviewandaward Council Review Date(s) http://grants1. nih. gov/grants/funding/submissionschedule.
htm#reviewandaward Earliest Anticipated Start Date(s): http://grants1. nih. gov/grants/funding/submissionschedule.
htm#reviewandaward letter of intent is not required for the funding opportunity. 3. B.
Sending an Application to the NIH To submit an application in response to this FOA, applicants should access this FOA via http://www. grants. gov/Apply and follow steps 1-4.
Note: Applications must only be submitted electronically . PAPER APPLICATIONS WILL NOT BE ACCEPTED. Applications may be submitted on or after the opening date and must be successfully received by Grants.
gov no applicant institution/organization) on the application submission/receipt date(s). (See Section IV. 3.
A . for all dates.) If an application is not submitted by the receipt date(s) and time, the application may be delayed in the review process or not reviewed.
Once an application package has been successfully submitted through Grants. gov, any errors have been addressed, and the assembled application has been created in the eRA Commons, the PD/PI and the Authorized Organization Representative/Signing Official (AOR/SO) have two business days to view the application image. If everything is acceptable, no further action is necessary.
The application will automatically move forward for processing by the Division of Receipt and Referral, Center for Scientific Review, NIH, after two business days. Prior to the submission deadline, the AOR/SO can Reject the assembled application and submit a changed/corrected application within the two day viewing window. This option should be used if the AOR/SO determines that warnings should be addressed.
Reminder: warnings do not stop further application processing. If an application submission results in warnings (but no errors) it will automatically move forward after two business days if no action is taken. Please remember that some warnings may not be applicable or may need to be addressed after application submission.
If the two day window falls after the submission deadline, the AOR/SO will have the option to Reject the application if, due to an eRA Commons or Grants. gov system issue, the application does not correctly reflect the submitted application package (e.g., some part of the application was lost or didn t transfer correctly during the submission process).
The AOR/SO should first contact the eRA Commons Helpdesk to confirm the system error, document the issue, and determine the best course of action. NIH will not penalize the applicant for an eRA Commons or Grants. gov system issue.
If the AOR/SO chooses to Reject the image after the submission deadline for a reason other than an eRA Commons or Grants. gov system failure, a changed/corrected application still can be submitted but it will be subject to the NIH late policy guidelines and may not be accepted.
The reason for this delay should be explained in the cover letter Both the AOR/SO and PD/PI will receive e-mail notifications when the application is rejected or the application automatically moves forward in the process after two days. Upon receipt, applications will be evaluated for completeness by the Center for Scientific Review, NIH. Incomplete applications There will be an acknowledgement of receipt of applications from Grants.
gov and the Commons . Information related to the assignment of an application to a Scientific Review Group is also in the NIH will not accept any application in response to this FOA that is essentially the same as one currently pending initial merit review unless the applicant withdraws the pending application. The NIH will not accept any application that is essentially the same as one already reviewed.
This does not preclude the submission of an application already reviewed with substantial changes, but such application must include an Introduction addressing the previous critique. Note such an application is considered a "resubmission" for 4.
Intergovernmental Review This initiative is not subject to intergovernmental All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Pre-Award Costs are allowable.
A grantee may, at its own risk and without NIH prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award if such costs: are necessary to conduct the project, and would be allowable under the grant, if awarded, without NIH prior approval.
If specific expenditures would otherwise require prior approval, the grantee must obtain NIH approval before incurring the cost. NIH prior approval is required for any costs to be incurred more than 90 days before the beginning date of the initial budget period of a new award.
The incurrence of pre-award costs in anticipation of a competing or non-competing award imposes no obligation on NIH either to make the award or to increase the amount of the approved budget if an award is made for less than the amount anticipated and is inadequate to cover the pre-award costs incurred.
NIH expects the grantee to be fully aware that pre-award costs result in borrowing against future support and that such borrowing must not impair the grantee's ability to accomplish the project objectives in the approved time frame or in any way adversely affect the conduct of the project. Grants Policy Statement .
The NIH requires the PD/PI to fill in his/her Commons User ID in the PROFILE Project Director/Principal Investigator section, Credential log-in field of the Research & Related Senior/Key Person Profile component. The applicant organization must include its DUNS number in its Organization Profile in the eRA Commons. This DUNS number must match the DUNS number provided at CCR registration with
Based on current listing details, eligibility includes: Not explicitly detailed in the snippet, but R21 grants generally support exploratory and developmental research by institutions and organizations. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Funding amounts vary based on project scope and sponsor guidance. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional) is sponsored by National Institute of Mental Health (NIMH), National Institutes of Health (NIH). This funding opportunity is a companion to the R21 mechanism and also aims to stimulate research to understand the link between social disconnection and suicidal thoughts and behaviors in late life. It focuses on identifying mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. This R01 mechanism is appropriate for applications with preliminary data.
Accelerating Solutions to Improve Access and Quality of Empirically-Supported Practices for Youth Mental Health (R01 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). This NOFO encourages research that studies methods to increase access to evidence-based interventions and services for youth mental health, particularly for those in rural, inner-city, and under-resourced areas, and youth experiencing homelessness. It addresses optimizing assessment, intervention, and service strategies, workforce shortages, waitlists, and integrating treatment and prevention into settings like schools, social services, pediatric medicine, and justice systems.
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This is a parent announcement for investigator-initiated research projects that do not involve a clinical trial. The R01 is the oldest and most common type of NIH research grant, supporting a wide range of research projects.